NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against Dr. Reddy’s Laboratories Ltd. (NYSE:RDY), if they purchased the Company’s securities between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Dr. Reddy’s investors should visit us at https://www.claimsfiler.com/cases/view-dr-reddys-laboratories-ltd-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Dr. Reddy’s and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had failed to implement an effective corporate quality control system including but not limited to its manufacturing plants and (ii) as a result of the foregoing, Dr. Reddy’s financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


Anta Sports Expands Global Footprint With Strategic Puma Stake
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Washington Post Publisher Will Lewis Steps Down After Layoffs
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



